LOGIN  |  REGISTER
Viking Therapeutics

Stryker to participate in the 2024 Wells Fargo Healthcare Conference

August 19, 2024 | Last Trade: US$361.36 2.59 -0.71

Portage, Michigan, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, at the Encore Boston Harbor.

Spencer Stiles, Group President, Orthopaedics and Spine, and Jason Beach, Vice President, Finance and Investor Relations will represent the Company in a session scheduled for 3:00 pm Eastern Time.

A simultaneous webcast and replay of the Company’s presentation will be available on Stryker’s website at www.stryker.com. The webcast will be archived on the Investor Relations page of this site.

About Stryker

Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries please contact:
Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it. 

For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB